German drug regulator considering export ban on Ozempic
FRANKFURT (Reuters) -The head of German drug regulator BfArM is considering an export ban on Novo Nordisk's diabetes drug Ozempic, which is in high demand for its weight-loss benefits, to prevent a worsened supply shortage. Ozempic is approved to treat type 2 diabetes but has increasingly been prescribed "off-label" to treat weight loss because it has the same active ingredient as Novo's hugely popular but scarce anti-obesity drug Wegovy.